CSF3, colony stimulating factor 3, 1440

N. diseases: 687; N. variants: 4
Disease: Carcinoma breast stage IV ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 Biomarker disease BEFREE This open label trial randomised 235 women with metastatic breast cancer to receive either high-dose epirubicin 150 mg/m<sup>2</sup> and cyclophosphamide 1500 mg/m<sup>2</sup> with filgrastim support every 3 weeks for 3 cycles (HDEC) or standard dose epirubicin 75 mg/m<sup>2</sup> and cyclophosphamide 750 mg/m<sup>2</sup> every 3 weeks for 6 cycles (SDEC). 31028610 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 GeneticVariation disease BEFREE Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer. 28929372 2018
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.030 Biomarker disease BEFREE In these studies, recombinant granulocyte colony stimulating factor (G-CSF) was administered to patients with metastatic breast cancer to increase the number of circulating stem cells. 8252190 1993